PT  - JOURNAL ARTICLE
AU  - Chanaka Kahathuduwa
AU  - Chathurika Dhanasekara
AU  - Shao-Hua Chin
TI  - Case fatality rate in COVID-19: a systematic review and meta-analysis
AID  - 10.1101/2020.04.01.20050476
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.01.20050476
4099  - http://medrxiv.org/content/early/2020/04/06/2020.04.01.20050476.short
4100  - http://medrxiv.org/content/early/2020/04/06/2020.04.01.20050476.full
AB  - Background Estimating the prevalence of severe or critical illness and case fatality of COVID-19 outbreak in December, 2019 remains a challenge due to biases associated with surveillance, data synthesis and reporting. We aimed to address this limitation in a systematic review and meta-analysis and to examine the clinical, biochemical and radiological risk factors in a meta-regression.Methods PRISMA guidelines were followed. PubMed, Scopus and Web of Science were searched using pre-specified keywords on March 07, 2020. Peer-reviewed empirical studies examining rates of severe illness, critical illness and case fatality among COVID-19 patients were examined. Numerators and denominators to compute the prevalence rates and risk factors were extracted. Random-effects meta-analyses were performed. Results were corrected for publication bias. Meta-regression analyses examined the moderator effects of potential risk factors.Results The meta-analysis included 29 studies representing 2,090 individuals. Pooled rates of severe illness, critical illness and case fatality among COVID-19 patients were 15%, 5% and 0.8% respectively. Adjusting for potential underreporting and publication bias, increased these estimates to 26%, 16% and 7.4% respectively. Increasing age and elevated LDH consistently predicted severe / critical disease and case fatality. Hypertension; fever and dyspnea at presentation; and elevated CRP predicted increased severity.Conclusions Risk factors that emerged in our analyses predicting severity and case fatality should inform clinicians to define endophenotypes possessing a greater risk. Estimated case fatality rate of 7.4% after correcting for publication bias underscores the importance of strict adherence to preventive measures, case detection, surveillance and reporting.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThe study was not funded. The authors have no potential conflicts of interest to declare.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in the manuscript is based entirely on data extracted from peer-reviewed, published research. The authors are willing to share detailed records of all steps including searching databases, systematically screening the literature, quality assessment, data extraction and meta-analysis (including the scripts).